What is it about?
Macular pigment confers potent antioxidant and anti-inflammatory effects at the macula. Macular pigment is not, however, routinely measured in clinical practice. In the current study we have provided additional evidence that low macular pigment may indeed be a feature of Type 2 diabetes. Furthermore we identified smoking, cataract and vitamin D status as plausible predictors of low MPOD amongst persons with Type 2 diabetes.
Featured Image
Why is it important?
Our findings suggest that individuals with Type 2 diabetes have lower macular pigment compared with healthy controls. Hyperglycemia and other anthropometric, metabolic and clinical correlates associated with diabetes (e.g. excess adiposity, dysllipidemia, hypertension and cataract) may relate to a state of chronic oxidative stress and inflammation, processes which may underlie many of the functional alterations in retinal vasculature in diabetic retinopathy and which may also contribute to lower levels of macular pigment in diabetes. Clinical benefits may be realised through the early identification of macular pigment depletion in Type 2 diabetes.
Read the Original
This page is a summary of: Identification of Surrogate Biomarkers for the Prediction of Patients at Risk of Low Macular Pigment in Type 2 Diabetes, Current Eye Research, July 2019, Taylor & Francis,
DOI: 10.1080/02713683.2019.1635166.
You can read the full text:
Contributors
The following have contributed to this page
